EAU 2013 - Programme Book - YouMed

Saturday
Saturday, 16 March - EAU Programme
114 Programme Book
Abstract Session
14.15 - 15.45 New therapies in castration resistant prostate cancer
Brown Hall 1-2 - Level S2
Poster Session 9
Chairs: T.A. Borkowski, Warsaw (PL)
M. De Santis, Vienna (AT)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate
(AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy
H. Van Poppel, D. Rathkopf, M.R. Smith, J.S. De Bono, C.J. Logothetis, N.D. Shore, P. De Souza, K. Fizazi,
P.F.A. Mulders, P. Mainwaring, J.D. Hainsworth, T.M. Beer, S. North, Y. Fradet, T. Griffin, Y.C. Park, T. Kheoh,
E.J. Small, H.I. Scher, A. Molina, C.J. Ryan (Leuven, Belgium; New York, Boston, Houston, Myrtle Beach,
Nashville, Portland, Los Angeles, Raritan, San Francisco, United States of America; Sutton, United Kingdom;
Liverpool, Brisbane, Australia; Villejuif, France; Nijmegen, The Netherlands; Edmonton, Quebec, Canada)
* 98 Combination therapy of peptide vaccines and dexamethasone for chemotherapy naïve castration resistant
prostate cancer - a randomized phase-2 study
H. Uemura, T. Kimura, K. Yoshimura, T. Minami, M. Nozawa, T. Nakagawa, H. Fujimoto, S. Egawa,
A. Yamada, K. Itoh (Osaka, Tokyo, Fukuoka, Japan)
99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with
nonmetastatic castration-resistant prostate cancer
D. Patrick, M.R. Smith, C. Cleeland, L. Fallowfield, B. Tombal, S. Oudard, N. Shore, F. Saad, G. Marx,
R. Coleman, F. Gómez-Veiga, R. Damião, Y. Zhou, J. Arellano, A. Braun, Y. Qian (Seattle, Boston, Houston,
Myrtle Beach, Thousand Oaks, United States of America; Brighton, Sheffield, United Kingdom; Brussels,
Belgium; Paris, France; Montreal, Canada; Wahroonga, Australia; A Coruna, Spain; Rio de Janeiro, Brazil)
100 Investigational single agent orteronel (ortl, TAK-700) in patients with nonmetastatic castration-resistant
prostate cancer (nmCRPC): Updated results
M. Hussain, P.G. Corn, D. Michaelson, H.J. Hammers, J.J. Alumkal, C.J. Ryan, J.Y. Bruce, S. Moran,
D. Maclean, S-Y. Lee, P. Mortimer, D.J. George (Ann Arbor, Houston, Boston, Baltimore, Portland, San
Francisco, Madison, Cambridge, Durham, United States of America; London, United Kingdom)
101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and
survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate
cancer (CRPC) and bone metastases
D. Heinrich, S.I. Helle, A. Chodacki, P. Wiechno, J. Garcia-Vargas, K. Staudacher, C. Parker (Lørenskog,
Bergen, Oslo, Norway; Chomutov, Czech Republic; Warsaw, Poland; Montville, New Jersey, United States of
America; Sutton, United Kingdom)
102 GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with
a significantly lower rate of hot flashes in men with advanced prostate cancer
R.H. Getzenberg, C.C. Coss, M.L. Hancock, J.T. Dalton, M.S. Steiner (Memphis, United States of America)
103 P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer
(mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC)
activation and cellular immune response data
T.M. Beer, J. Corman, R. Sims, Y. Wang, C. De La Rosa, N. Sheikh (Portland, Seattle, United States of
America)